Recently, Shanghai Novamab Biopharmaceuticals Co., Ltd. (hereinafter referred to as Novamab) announced the completion of a Series B financing round exceeding 100 million RMB. This round was led by Shanghai SDIC Fund Management Co., Ltd. (referred to as "SDIC Investment"), with existing shareholder Chengdu BioCity Fund (Guosheng Capital) also increasing their investment.
This round of funding will be used for Phase II clinical research of two inhaled antibody drugs (LQ036, LQ043) independently developed by the company based on its "Inhaled Large Molecule Drug Development Platform," and to further expand the team and supplement the company’s working capital. Meanwhile, Novamab's Series B+ financing is currently underway.
Novamab is an innovator in the research and development of inhalable nanobody drugs, focusing on the development of nanobody innovative drugs in the respiratory and autoimmune fields. The company has a high-level foundation in nanobody drug research and development and has established an integrated, systematic, and comprehensive professional development platform. It has independently created five core technology platforms based on nanobodies: a rapid nanobody screening platform, a Pichia pastoris CMC process development platform, an inhalable macromolecular drug research and development platform, a long-acting nanobody platform, and a bispecific nanobody platform. Each platform has unique industry advantages, enabling the rapid screening of nanobody drugs with pharmaceutical activity and their swift industrialization.
Dr. Yaqun Wan, founder of Novamab, stated: "We will efficiently utilize this round of funding to advance our core pipeline of inhaled nanobodies to critical clinical milestones, fully validating the product's efficacy and further ensuring its safety. In the future, the company will continue to uphold the vision of 'Camel antibodies initiating a healthy future, building a world-leading nanobody drug R&D enterprise,' focusing on nanobodies, addressing clinical issues, and leveraging our core technology platform to continuously introduce innovative drug products with greater differentiation and competitiveness. We aim to address unmet clinical needs and benefit more patients."
Shengdi Investment, the lead investor of this round of financing, stated: Nanobodies have become a new popular breakthrough direction in global antibody drug research and development, offering unique advantages in developing inhaled biologics for respiratory diseases. Novamab has established a mature nanobody discovery platform, an inhaled macromolecular drug R&D platform, and a Pichia pastoris CMC development platform. The two inhaled nanobody drugs that have entered the clinical stage demonstrate clear advantages over injectable drugs in terms of onset speed, compliance, safety, and cost. The founding team has a forward-looking vision and unique technical barriers in the field of nanobodies, with the ability to carry out full-process nanobody development and the potential to continuously develop blockbuster products.